Pharma Minds
✓

Pharma Minds

OM DENNE PODCAST 🔗

Bienvenue dans Pharma minds, le podcast qui vous emmène dans une aventure captivante à travers la Pharma et la Santé d'aujourd'hui ! Je suis votre hôte, Nathalie Lahitte. Mon objectif ? Découvrir comment des personnalités influentes ont contribué à façonner ce secteur.
À chaque épisode, nous plongeons dans leurs caractéristiques uniques, dévoilant les secrets de leurs parcours exceptionnels et leur rôle dans les grandes transformations de cet écosystème.
Explorez les coulisses de l'évolution de la Pharma et de la Santé à travers des discussions authentiques et percutantes. Ensemble, nous construisons l'avenir de ce secteur fascinant en le rendant plus innovant et inclusif. Rejoignez-nous pour des épisodes inspirants et motivants, et soyez aux premières loges de la Santé de demain.
🎧 Vous êtes nouveau par ici ? Pour comprendre en un clin d'œil le panorama des épisodes, téléchargez « 25 conseils pour un leadership engagé (https://pharma-minds.kit.com/ebookleadership) », un guide inspiré des meilleurs conseils de mes invités.
🤝 Vous voulez me parler ou échanger sur vos enjeux ? Connectons-nous sur LinkedIn (https://www.linkedin.com/in/nathalielahitte/).
📩 Et si vous voulez aller plus loin dans la compréhension des grandes transformations de l’écosystème pharma et santé, abonnez-vous à la newsletter Pharma Minds (https://nathalielahitte.substack.com/).
Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.
Forretning
Karriere
Værter:
Opdateringsfrekvens:
weekly
Gennemsnitlig lydlængde:
29 minutes
Gæsteinterviews
Har sponsorer
Fransk
Frankrig
143 episoder
siden 15. maj 2023
episodic
BrugAPItil at hente denne podcast iJSON

SENESTE EPISODE 🔗

"Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced

"Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced

What if Europe’s “innovation wave” isn’t quite what we think it is? In this bonus episode of Pharma minds’ Europe’s Access Dilemma, I speak with Dr. Sabine Vogler, health economist, Head of the Pharmacoeconomics Department at the Austrian National Public Health Institute (GÖG) and of the WHO Colla…
00:25:11
DEL
GEM

SØG BLANDT TIDLIGERE EPISODER

Søg efter gamle afsnit af Pharma Minds.
Integrer denne søgefelt på dit websted

SIDSTE EPISODER

"Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up?

"Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up?

"The worst of all outcomes is the current default: the level of Europe's contribution to the world will be decided by America." – Graham Cookson, Economist Welcome to the 5th episode of Europe's Access Dilemma, the Pharma Minds mini-series on MFN and access to innovation in Europe. Pay more. Wait …
00:27:45
DEL
GEM
"Europe's Access Dilemma" (4/5) - Pharma Innovation: Your 8-Year Competitive Window Is Now Just 3

"Europe's Access Dilemma" (4/5) - Pharma Innovation: Your 8-Year Competitive Window Is Now Just 3

What happens to pharmaceutical innovation when your competitive window shrinks from eight years to just three? In this episode of Pharma minds, I speak with Marine Baxendell, CFO and co-fonder at xcube.bio, about a fundamental shift in the economics of pharma innovation. Science is moving faster.…
00:30:53
DEL
GEM
"Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.

"Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.

MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines. In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and biotech leaders sta…
00:30:17
DEL
GEM
"Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia

"Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia

What if Europe’s answer to the rising cost of pharmaceutical innovation wasn’t simply to pay more, but to develop differently? In this episode of Pharma minds, I speak with Franck Le Deu, one of the few European voices with decades of first-hand experience inside Asia’s rapidly evolving biopharma …
00:31:20
DEL
GEM
"Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why.

"Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why.

What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation? In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most conseque…
00:30:33
DEL
GEM
[Insights] Produits frontières : transformer la réglementation en avantage stratégique

[Insights] Produits frontières : transformer la réglementation en avantage stratégique

Compléments alimentaires, cosmétiques, huiles essentielles, biocides, laits infantiles... Certains produits se situent à la frontière de plusieurs catégories réglementaires. Et selon leur composition, leur destination ou leur présentation, leur statut peut changer. Dans cet épisode de Pharma Minds…
00:14:19
DEL
GEM
"Executing differently takes courage" (5/5) - From managing global subsidiaries to walking the talk : when execution becomes personal

"Executing differently takes courage" (5/5) - From managing global subsidiaries to walking the talk : when execution becomes personal

Organizations demand infinite growth in finite markets. Leaders are left at the crossroads of irreconcilable missions, balancing economic imperatives with the well-being of their teams. What happens when the equation simply has no solution? The cost of execution is sometimes your own breaking point…
00:24:55
DEL
GEM
"Executing differently takes courage" (4/5) - Biotech survival and resource allocation : why execution is about choosing what not to do

"Executing differently takes courage" (4/5) - Biotech survival and resource allocation : why execution is about choosing what not to do

You can have the best science in the world, but it means nothing if your company runs out of cash. When resources are limited and markets are unforgiving, execution ceases to be a management theory. It becomes a strict matter of survival. What does it actually cost to fund biotech innovation withou…
00:27:30
DEL
GEM
"Executing differently takes courage" (3/5) - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone

"Executing differently takes courage" (3/5) - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone

What do we do when the ground is unstable and information is incomplete? We are told to wait for the right conditions. But what if waiting costs more than acting? The real risk is failing to achieve your purpose. Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I chose …
00:23:12
DEL
GEM
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra Nathalie Lahitte, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
PODCAST SØGEMOTOR
Du kan bruge vores hjemmeside til at søge efter3,823,287podcasts og195,638,723episoder efter personer, steder eller emner.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of giants.  ‐ Isaac "Llamacorn" Newton

ANBEFALINGER

Brug API til at hente denne podcast